Anticytokine therapy with interleukin-17 in patients with moderate and severe psoriasis
- Authors: Kovaleva J.S.1, Kazantsev I.V.2, Aibazova A.A.2, Ovchinnikova E.O.2, Garina A.A.2, Shabaldina A.P.2
-
Affiliations:
- Altay State Medical University
- Regional Dermatovenereologic Dispensary Altai Territory
- Issue: Vol 100, No 1 (2024)
- Pages: 93-103
- Section: CLINICAL CASE REPORTS
- URL: https://journals.rcsi.science/0042-4609/article/view/254525
- DOI: https://doi.org/10.25208/vdv15341
- ID: 254525
Cite item
Full Text
Abstract
Clinical observations of three patients aged 26, 43 and 37 years with severe psoriasis and psoriatic arthritis are presented. Clinical examples show the experience of effective treatment of patients with psoriasis and psoriatic arthritis using anti-cytokine therapy with an interleukin-17 inhibitor, initiated when the disease progresses. The clinical picture of the presented observations was characterized by an aggressive course of the skin and articular process, torpidity to basic therapy, despite the young age of the patients. It has been shown that the early termination of the progression of the inflammatory process in psoriasis with the use of genetically engineered biological therapy with secukinumab leads to a decrease in symptoms, both on the part of the skin and manifestations of the disease on the part of the musculoskeletal system. The high efficacy and safety of the drug allow complete control of the disease and improve the quality of life in patients suffering from severe forms of dermatosis.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Julia S. Kovaleva
Altay State Medical University
Author for correspondence.
Email: julia_jsk@mail.ru
ORCID iD: 0000-0002-4401-3722
MD, Dr. Sci. (Med.), Assistant ProfessorRussian Federation, Barnaul
Igor V. Kazantsev
Regional Dermatovenereologic Dispensary Altai Territory
Email: priemnaya.kkvd@mail.ru
Dermatovenereologist
Russian Federation, BarnaulAnnetta A. Aibazova
Regional Dermatovenereologic Dispensary Altai Territory
Email: annetta.aybazova@mail.ru
Dermatovenereologist
Russian Federation, BarnaulEkaterina O. Ovchinnikova
Regional Dermatovenereologic Dispensary Altai Territory
Email: docovchinnikova@mail.ru
Dermatovenereologist
Russian Federation, BarnaulAnastasia A. Garina
Regional Dermatovenereologic Dispensary Altai Territory
Email: vika.garina.1988@mail.ru
Dermatovenereologist
Russian Federation, BarnaulAnastasia P. Shabaldina
Regional Dermatovenereologic Dispensary Altai Territory
Email: nastya_190589@mail.ru
Dermatovenereologist
Russian Federation, BarnaulReferences
- Кубанов А.А., Карамова А.Э., Притуло О.А., Аршинский М.И., Знаменская Л.Ф., Чикин В.В. и др. Псориаз: клинические рекомендации. М.; 2023. [Kubanov AA, Karamova AE, Pritulo OA, Arshinskij MI, Znamenskaja LF, Chikin V.V. et al. Psoriaz: Klinicheskie rekomendacii. Moscow; 2023. (In Russ.)] URL: https://cr.minzdrav.gov.ru/schema/234_2
- Bulat V, Šitum M, Delaš Aždajić M, Lovrić I, Dediol I. Study on the Impact of Psoriasis on Quality of Life: Psychological, Social and Financial Implications. Psychiatr Danub. 2020;32(Suppl 4):553–561.
- Круглова Л.С., Моисеев С.В. Блокада интерлейкина-17 — новые горизонты эффективности и безопасности в лечении псориаза. Клиническая фармакология и терапия. 2017;26(2):5–12. [Kruglova LS, Moiseev SV. Interleukin-17 blockade — new horizons of efficacy and safety in the treatment of psoriasis. Klinicheskaya farmakologiya i terapiya = Clinical pharmacology and therapy. 2017;26(2):5–12. (In Russ.)]
- Коротаева Т.В., Корсакова Ю.Л. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2018;56(1):60–69. [Korotayeva TV, Korsakova YuL. Psoriatic arthritis: classification, clinical picture, diagnosis, treatment. Nauchno-prakticheskaya revmatologiya, Nasonova Research Institute of Rheumatology. 2018;56(1):60–69. (In Russ.)] doi: 10.14412/1995-4484-2018-60-69
- Jankowiak B, Kowalewska B, Krajewska-Kułak E, Kowalczuk K, Khvorik DF. The Sense of Stigmatization in Patients with Plaque Psoriasis. Dermatology. 2021;237(4):611–617. doi: 10.1159/000510654
- Кубанов А.А., Богданова Е.В. Эпидемиология псориаза в Российской Федерации (по данным регистра). Вестник дерматологии и венерологии. 2022;98(2):33–41. [Kubanov AA, Bogdanova EV. Epidemiology of psoriasis in the Russian Federation according to the register. Vestnik Dermatologii i Venerologii. 2022;98(2):33–41. (In Russ.)] doi: 10.25208/vdv1268
- Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.е19. doi: 10.1016/j.jaad.2018.06.027
- Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol. 2007;57(6):1059–1068. doi: 10.1016/j.jaad.2007.07.016
- Олисова О.Ю., Гаранян Л.Г. Эпидемиология, этиопатогенез и коморбидность при псориазе — новые факты. Российский журнал кожных и венерических болезней. 2017;20(4):214–219. [Olisova OYu, Garanyan LG. Epidemiology, etiopathogenesis and comorbidity in psoriasis — new facts. Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney = Russian journal of skin and venereal diseases. 2017;20(4):214–219. (In Russ.)] doi: 10.18821/1560-9588-2017-20-4-214-219
- Rouvier E, Luciani MF, Mattéi MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993;150(12):5445–5456.
- Van den Berg WB, McInnes IB. Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum. 2013;43(2):158–170. doi: 10.1016/j.semarthrit.2013.04.006
- Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888–898. doi: 10.1056/NEJMra0707449
- Frleta M, Siebert S, McInnes IB. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibili- ties of treatment. Curr Rheumatol Rep. 2014;16(4):414. doi: 10.1007/s11926-014-0414-y
- Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoform and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–324. doi: 10.1111/j.1365- 2133.2008.08902.x
- Коротаева Т.В. Перспективы применения ингибиторов интерлейкина-17 — нового класса препаратов для таргетной терапии псориатического артрита. Научно-практическая ревматология. 2016;54(3):346–351. [Korotaeva TV. Prospects for using interleukin-17 inhibitors, a new class of drugs for targeted therapy of psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):346–351. (In Russ.)] doi: 10.14412/1995-4484-2016-436-351
- Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E. Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol. 2010;6(12):704–714. doi: 10.1038/nrrheum.2010.157
- Зильберберг Н.В., Кащеева Я.В., Кохан М.М. Опыт применения препарата секукинумаб в терапии больных псориазом. Лечащий врач. 2021;10:41–45. [Zilberberg NV, Kascheeva YaV, Kokhan MM. Experience of using secukinumab in the treatment of patients with psoriasis. Lechaschi Vrach. 2021;10:41–45. (In Russ.)] doi: 10.51793/OS.2021.24.10.007
- Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis. Results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258
- Thaçi D, Blauvelt A, Reich K., Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. doi: 10.1016/j.jaad.2015.05.013
Supplementary files
